News and Trends 31 Jan 2023
BiVictriX announces positive data from leukemia study
…and provide further evidence that our first-in-class platform offers the potential to deliver the next generation of highly selective, anti-cancer therapies. Generating data that demonstrates BVX001 was well-tolerated in this…